According to the CDC, approximately six million Americans are living with Alzheimer's disease, but access to experimental, potentially life-saving drugs is limited. For impacted veterans, the Veterans Health Administration is looking for ways to provide that access.
Last year, Biogen, in partnership with Japanese drug company Eisai, announced that the drug called Leqembi showed promise in slowing cognitive decline in Alzaheimer's patients by 27 percent. The VHA announced it will shell out more than $26,000 annually for each veteran on Leqembi. If the FDA grants a full approval by July 6, Medicare and Medicaid services said it would immediately provide broad coverage of the drug to customers.
The experimental treatment received Accelerated Approval by the Food and Drug administration earlier this year. The specific pathway to approval had been introduced by the agency to provide speedier clearance on drugs that treat serious conditions.
Last month the Centers for Medicare and Medicaid Services declined to provide unrestricted coverage of the drug because "there is not yet evidence meeting the criteria for reconsideration."
"This standard differs from the criteria used by the FDA to assess whether medications are safe and effective. We are aware that additional publications may be forthcoming that include information relevant to the questions included in the current NCD," the agency added in its statement.
America’s honeybee hives just staggered through the second highest death rate on record, with beekeepers losing nearly half of their managed colonies, an annual bee survey found.
A line of severe storms produced what a meteorologist calls a rare combination of multiple tornadoes, hurricane-force winds and softball-sized hail in west Texas, killing at least four people, injuring nine and causing significant damage around the town of Matador, a meteorologist said Thursday.
The Biden administration proposed bringing back rules to protect imperiled plants and animals on Wednesday as officials moved to reverse changes under former President Donald Trump that weakened the Endangered Species Act.
For the first time, U.S. regulators on Wednesday approved the sale of chicken made from animal cells, allowing two California companies to offer “lab-grown” meat to the nation's restaurant tables and eventually, supermarket shelves.
